Ultra small molecule as a new target for Alzheimer’s disease?
15 June 2023
15 June 2023
A new study from the Netherlands Institute for Neuroscience and the VIB-KU Leuven Center for Brain and Disease Research shows that a very small molecule called microRNA-132 can have a significant impact on different brain cells and may play a role in Alzheimer’s disease.
RNA is a molecule that, like DNA, consists of a series of linked building blocks. RNA was long thought to only serve as a messenger and copy of DNA, enabling the translation of DNA into proteins. However, there are also pieces of RNA that do not encode for proteins. MicroRNAs are an example of these non-coding RNA molecules. Despite being small in size, they can have a major function: they can bind to RNA and thereby influence the expression of genes and proteins. In many different diseases, including Alzheimer’s, microRNAs are often dysregulated.
Alzheimer’s patients often exhibit disrupted and altered microRNA profiles, particularly a significant decrease in microRNA-132. But does this molecule truly play a role in the disease, or is this decrease merely coincidental? Previous studies in mouse models have shown that increasing levels of microRNA-132 resulted in the generation of new brain cells and improved memory in the mice. While many researchers believe that the protein amyloid is the primary cause of Alzheimer’s disease, another protein called tau and inflammation also appear to play important roles. MicroRNA-132 has shown a positive effect on both amyloid and tau pathologies in mice. However, the exact mechanisms are still unknown.
Researchers Hannah Walgrave, Amber Penning, Sarah Snoeck, Giorgia Tosoni, and their team, led by Evgenia Salta (in collaboration with the group of Bart De strooper at KU Leuven-VIB, Belgium) investigated the effects of microRNA-132 in different cell types. They manipulated the levels of microRNA-132 in a mouse model by both increasing and decreasing them. Subsequently, they used a special technique called single-cell RNA sequencing to examine the genes that changed in each cell type in the brain.
Amber Penning: “A microRNA can have numerous targets, which makes them interesting for diseases with multiple pathological aspects. However, this also makes them challenging to study because how do you find those targets? We know that microRNA-132 performs various functions in neurons, but surprisingly, we found that this microRNA also plays a role in microglia, the immune cells of the brain. This is interesting in the case of Alzheimer’s because we believe that neuroinflammation plays a significant role.”
“When we increase microRNA-132 in these microglia, we observe a shift from a disease-associated state to a more balanced homeostatic state. We see this result in both mouse brain and human cell lines. However, whether this change is positive or negative requires further investigation through follow-up experiments. There are different theories suggesting that this disease-associated state may initially aid in cell clearance during the early stages of the disease but becomes excessive later, leading to the death of healthy cells. We still need to determine how beneficial it is for the cells to become more homeostatic. Therefore, we need to be cautious in drawing conclusions.”
“The most significant aspect of this study is demonstrating that microRNA-132 also plays a role in microglia and can influence neuroinflammation. The next step is to examine whether increasing microRNA-132 in neurons and microglia in an Alzheimer’s mouse model has any actual effect. The same applies to the human cell lines we used. In this research, we only used a healthy control cell line, but we will conduct further tests in Alzheimer’s cell lines to see if there are any effects.”
“The ultimate goal would be to increase microRNA-132 in Alzheimer’s patients as a therapeutic strategy. Currently, we are using viruses (containing the microRNA) in Alzheimer’s mice that can be injected intravenously, directly into the veins. This makes it easier to eventually translate this strategy to the clinic, as we are utilizing a virus that, in theory, can also be injected into an arm. In addition to Alzheimer’s, there are other neurodegenerative diseases that exhibit a decrease in the same microRNA. Therefore, these results may also be relevant to other disease conditions.”
Source: iScience Cell Press